Dr. Lai on the Potential Benefits of Venetoclax in AML


In Partnership With:

Catherine Lai, MD, MPH, discusses ​the potential benefits of venetoclax in acute myeloid leukemia.

Catherine Lai, MD, MPH, director of Leukemia at MedStar Georgetown University Hospital’s Lombardi Comprehensive Cancer Center, discusses ​the potential benefits of venetoclax (Venclexta) in acute myeloid leukemia (AML). 

Many advances have been made in the AML armamentarium, and chief among them is venetoclax, explains says Lai. 

The drug plays a significant role in the treatment of patients with newly diagnosed AML who are older and are unfit for intensive chemotherapy​, Lai explains.

Although the response rates with venetoclax are similar to several induction chemotherapy regimens, the toxicity profile is improved with the BCL-2 inhibitor. ​Additionally, venetoclax can be given in the outpatient setting, which is of critical importance for older, high-risk patients during the coronavirus disease 2019 pandemic, Lai concludes. 

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD